Fat loss
AOD-9604 Dosage: A Fat-Loss Peptide That Flopped
A fat-loss peptide whose own pivotal trial did not beat placebo.
The quick version
- A growth-hormone fragment marketed for fat loss.
- Its own phase 2b trial failed to beat placebo, and it was dropped.
- Better-evidenced fat-loss tools exist.
What it is
AOD-9604 is a fragment of growth hormone, marketed for fat loss without affecting blood sugar or growth. It was developed as an obesity drug, then dropped.
What the research shows
Here is the part the sellers skip: in the larger phase 2b trial, AOD-9604 did not beat placebo for weight loss, and the maker discontinued it as an obesity drug in 2007 (obesity pharmacotherapy review). An earlier small study hinted at a couple of kilos, but the big test did not hold up. The pitch outran the data.
What it felt like
I have not run AOD-9604. Given that the pivotal trial failed, I have never seen a reason to spend money on it over options with real data.
Dosing reality
Community doses float around 300 mcg per day, but since the drug failed its trials and is unapproved, there is no dose I would call evidence-based. The number is borrowed from marketing, not results.
The one mistake to avoid
The mistake is buying it as a modern fat-loss tool. The clinical story already played out, and it did not win.
Bottom line
AOD-9604 is a fat-loss peptide whose own trials did not support the hype. There are better-evidenced tools.
Reminder: I am not a doctor and this is not medical advice. It is my own notes and reading of the research. Peptides sit in a legal grey area, research-grade is a real category, and it is on you to verify your own compliance. Talk to a qualified professional before you start anything, especially if you take other medication.